TNFSF13 and essential thrombocythemia: Our study evaluated systemic and bone marrow concentrations of APRIL and BAFF and their receptors in ET patients, and showed their significantly higher concentrations in peripheral blood, regardless of the presence of the JAK2(V617F) mutation.